



HELPING HEALTH SYSTEMS BETTER PREPARE FOR BREAKTHROUGH MEDICINES: PROFILING AN INNOVATIVE NEW TOOL



January 17, 2025



12:00 PM EST



MARTINE ELIAS

Chief Executive Officer at Myeloma Canada and Co-
Chair of the Collective Oncology Network for
Exchange



GRAHAM STATT

Former ADM of Alberta Drug Program and
Vice Chair of pCPA



ROSS WALLACE

Principal, Santis Health




Video Demonstration of the System Readiness Tool

Focusing on the “Last Mile” of Market Access

What is I2U?

Patients Need Innovation AND Implementation



- The development of breakthrough therapies is advancing at a faster rate than ever before.
- Unfortunately, the delivery of those same therapies is falling farther behind – due to the **increasing complexity of implementation**.
- There is a huge need across Canada to **connect drug plans and health system leaders** to maximize the value of these therapies.

What is I2U?

Improving the Implementation of Therapies



Through a country comparator jurisdictional scan, we found that although time and resources are dedicated to the approval process, **maximizing breakthrough therapies after reimbursement** is often less of a priority.



We found that there is a **huge need to work collaboratively to identify – and address – the barriers and obstacles** preventing health system leaders from more readily bringing new therapies to patients.



I2U's independent advisory board helps direct our efforts and validate our findings. Although Novartis provided initial funding, this work has neither a therapeutic focus nor a company one.



MYELOMA
CANADA
MAKING MYELOMA MATTER



Relying on Internal and External Experts

Our “In-House” Experts

Guided by an Independent Advisory Board

The I2U Advisory Board is composed of 7 former public payers, academics, practicing clinicians, innovation experts, and patient group representatives:



Dr. Shaan Chugh
Internal Medicine Physician,
Trillium Health Partners



Martine Elias
CEO, Myeloma Canada
Co-Chair, ACTION



Zayna Khayat
Health Futurist, Deloitte Canada
Growth Advisor, Teladoc Health



Marcel Saulnier
Former Associate ADM,
Health Canada



Graham Statt
Former ADM,
Drug Plan in Alberta



Helen Stevenson
Founder and CEO,
Reformulary Group



Dr. Robyn Tamblyn
Professor of Medicine,
McGill University Health Centre



Engaging with Payers and Policymakers

I2U Was Also Informed by Government Interviews

I2U Advisory Board members spoke with 20+ payers and policymakers across the country. They took away some key insights:

- I2U's focus on **post-listing implementation** is important and distinctive.
- Getting health systems ready for these therapies is a **shared goal across the broader pharma policy ecosystem**.
- Part of the **solution is moving beyond sequential analysis** to a **more integrated approach**.

These insights helped I2U identify a mix of case studies that highlighted barriers to implementation after funding challenges have been addressed.

Engaging with Payers and Policymakers

A Wide Range of System Interviewees (I)

Organization	Title
<i>CADTH / CDA</i>	Vice-President, Pharmaceutical Reviews
	Vice-President, Strategic Relationships and Initiatives
	Executive Vice-President, Evidence, Products and Services
	President & CEO
<i>pCPA</i>	Former pCPA Chair, & ADM, Pharmaceutical, Laboratory & Blood Services Division, British Columbia
	pCPA Board Member, & ADM, System Overview and Strategic Services, Alberta
	pCPA Board Member, & ADM, Health Programs and Delivery, General Manager of OHIP, and Executive Officer of Drugs, Ontario
<i>INESSS</i>	President-Directrice generale
<i>Health Canada</i>	Director General, Pharmaceutical Drugs Directorate
	Associate Assistant Deputy Minister

Engaging with Payers and Policymakers

A Wide Range of System Interviewees (II)

<i>Organization</i>	<i>Title</i>
<i>ON Ministry of Health, Lab & Diagnostics Branch</i>	Director, Lab & Diagnostics Branch
	Manager, Lab & Diagnostics Branch
	Manager, Policy Development
	Senior Program Consultant
	Senior Program Consultant
<i>Ontario Hospital Association</i>	President & CEO
<i>ON Ministry of Health</i>	Director, Ontario Public Drug Programs
<i>Government of Alberta</i>	Former ADM, Pharmaceutical and Supplementary Benefits Division
<i>Alberta Health Services</i>	Director of Pharmacy, Cancer Services
	VP and CEO, Clinical Operations
<i>NB Ministry of Health</i>	Co-CEO, New Brunswick Cancer Network
<i>BC Ministry of Health</i>	Director, Precision Medicine and Genetic Services

Assessing System Readiness: Building Toward a New Tool

Improving the Implementation of Breakthrough Therapies

Developing a System Readiness Tool



PHASE 1

Jurisdictional Scan:


How are comparator countries addressing the challenge of optimizing utilization?



PHASE 2

Case Studies & System Leader Conversations:

Identifying the key system barriers delaying patient access to breakthrough therapies.



PHASE 3

System Readiness Tool:

Helping health system leaders, patient groups, and manufacturers identify & overcome system barriers.

The three phases outlined above have paved the way for our remarkable journey, bringing us to the exciting point we find ourselves at today.



MYELOMA
CANADA

MAKING MYELOMA MATTER

The Payer & Patient Perspective on System Readiness

Q&A

Our Ask of You

1. **Please use the Tool** to support your efforts to improve the implementation of breakthrough therapies.
2. **Please share your feedback and advice** so we can better understand what's working, what's not and how to make it better.

Please share your input with us – or via info@I2U.ca



Access the Tool here